

Resource Summary Report

Generated by [RRID](#) on Aug 6, 2026

IGF-I Receptor (D23H3) XP Rabbit mAb

RRID:AB_10950969

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9750, RRID:AB_10950969

Antibody Information

URL: http://antibodyregistry.org/AB_10950969

Proper Citation: Cell Signaling Technology Cat# 9750, RRID:AB_10950969

Target Antigen: IGF-I Receptor (D23H3) XP Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IF-IC, F. Consolidation on 7/2016: AB_10949773.

Antibody Name: IGF-I Receptor (D23H3) XP Rabbit mAb

Description: This monoclonal targets IGF-I Receptor (D23H3) XP Rabbit mAb

Target Organism: rat, h, m, mouse, r, human, mk

Antibody ID: AB_10950969

Vendor: Cell Signaling Technology

Catalog Number: 9750

Alternative Catalog Numbers: 9750S, 9750P

Record Creation Time: 20250820T070246+0000

Record Last Update: 20250821T012856+0000

Ratings and Alerts

- Used for 9750S by the Human Islet Research Network community. Contact(s): <https://www.ncbi.nlm.nih.gov/pubmed/30316806> - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for IGF-I Receptor (D23H3) XP Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 40 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Yamsek M, et al. (2026) Structural basis of regulated N-glycosylation at the secretory translocon. *Nature*, 649(8097), 777.

Baro M, et al. (2025) Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation. *Cell chemical biology*, 32(6), 839.

Daley BR, et al. (2025) SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma. *Cancer research*, 85(1), 118.

Li H, et al. (2025) Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy. *Cell reports. Medicine*, 6(2), 101927.

Medina EF, et al. (2025) System analysis links SMARCD3 regulons to growth signaling and MEK inhibitor response in everolimus-resistant ER+ breast cancer cells. *Cell reports. Medicine*, 6(11), 102425.

Palmer CL, et al. (2025) CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. *Cancer cell*, 43(3), 464.

Chhabra Y, et al. (2024) Roles of Growth Hormone-Dependent JAK-STAT5 and Lyn Kinase Signaling in Determining Lifespan and Cancer Incidence. *Endocrinology*, 165(11).

Shiba-Ishii A, et al. (2024) Novel therapeutic strategies targeting bypass pathways and mitochondrial dysfunction to combat resistance to RET inhibitors in NSCLC. *Biochimica et biophysica acta. Molecular basis of disease*, 1870(6), 167249.

Li K, et al. (2024) Growth hormone promotes the reconstruction of injured axons in the hypothalamo-neurohypophyseal system. *Neural regeneration research*, 19(10), 2249.

Song H, et al. (2024) Burdock miR8175 in diet improves insulin resistance induced by obesity in mice through food absorption. *iScience*, 27(5), 109705.

Hurcombe JA, et al. (2024) Contrasting consequences of podocyte insulin-like growth factor 1 receptor inhibition. *iScience*, 27(5), 109749.

Marrocco I, et al. (2023) L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab. *Cell reports. Medicine*, 4(8), 101142.

Yu Y, et al. (2023) PTEN phosphatase inhibits metastasis by negatively regulating the Entpd5/IGF1R pathway through ATF6. *iScience*, 26(2), 106070.

Lopez-Tello J, et al. (2023) Fetal manipulation of maternal metabolism is a critical function of the imprinted Igf2 gene. *Cell metabolism*, 35(7), 1195.

Guay KP, et al. (2023) A quinolin-8-ol sub-millimolar inhibitor of UGGT, the ER glycoprotein folding quality control checkpoint. *iScience*, 26(10), 107919.

Wurm AA, et al. (2023) Signaling-induced systematic repression of miRNAs uncovers cancer vulnerabilities and targeted therapy sensitivity. *Cell reports. Medicine*, 4(10), 101200.

Hu H, et al. (2023) Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin-Drug Conjugate Response. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(17), 3457.

Kim S, et al. (2023) Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma. *Cell reports*, 42(6), 112570.

Chessa TAM, et al. (2023) PLEKHS1 drives PI3Ks and remodels pathway homeostasis in PTEN-null prostate. *Molecular cell*, 83(16), 2991.

Ma R, et al. (2022) Insights Into Ferroptosis: Targeting Glycolysis to Treat Graves' Orbitopathy. *The Journal of clinical endocrinology and metabolism*, 107(7), 1994.